Trevor Anthony Mill
Corporate Officer/Principal chez COMPASS PATHWAYS PLC
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Steven John Green | M | 47 |
Silver Acquisition Co. Ltd.
 Silver Acquisition Co. Ltd. BiotechnologyHealth Technology Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation.
Convergence Pharmaceuticals Holdings Ltd.
 Convergence Pharmaceuticals Holdings Ltd. Financial ConglomeratesFinance Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The company is based in Maidenhead, UK.
Old Convergence Pharmaceuticals Ltd.
 Old Convergence Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The company is based in Maidenhead, UK.
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | 10 ans |
| Mary-Rose Hughes | F | - | 4 ans | |
| Douglas Lankler | M | 58 | 25 ans | |
| David Norton | M | 72 | 6 ans | |
| Thomas Lönngren | M | 73 | 5 ans | |
| Nicole Murphy | F | - | 9 ans | |
| Kabir Kumar Nath | M | 59 | 2 ans | |
| Michael Hencke | M | - | 12 ans | |
| Jesus Mantas | M | 55 | 5 ans | |
| Sally Susman | F | 62 | 17 ans | |
| David Witty | M | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Annalisa Jenkins | M | 58 | 6 ans | |
| William Hawkins | M | 70 | 5 ans | |
| Joanne Palmer | F | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Suzanne Johnson | F | 66 | 17 ans | |
| Robert McQuade | M | 67 | 4 ans | |
| Wayne Riley | M | 64 | 3 ans | |
| Linda McGoldrick | M | 69 | 4 ans | |
| Anne Benedict | F | - | 3 ans | |
| Guy Goodwin | M | 76 | 3 ans | |
| Mike McDermott | M | 58 | 21 ans | |
| Matthew Owens | M | 46 | 2 ans | |
| Ged Giblin | M | - |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Gary Gilmour | M | - | - | |
| Stephen D. Schultz | M | - | 4 ans | |
| Ben Harber | M | - | - | |
| Annaliesa Anderson | M | - | 17 ans | |
| Barbara Dalton | M | 69 | 17 ans | |
| Greg Ryslik | M | - | - | |
| Markus Green | M | - | 18 ans | |
| Lorraine Deborah Barr | F | 58 |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | - |
| Denis Patrick | M | - | 14 ans | |
| Natacha Gassenbach | F | - | 6 ans | |
| Anabella Villalobos | M | 65 | 7 ans | |
| Thomas Insel | M | 72 | - | |
| Christopher Williams | M | - | - | |
| Neil Raymond Sisak | M | 53 |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | - |
| Daphne Karydas | F | 49 | 1 ans | |
| Jake Elkins | M | - | 7 ans | |
| Suneet Varma | M | 55 | 23 ans | |
| Robin Kramer | F | 58 | 6 ans | |
| Valerie Morisset | M | 55 |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | - |
| Ginger Gregory | M | 56 | 7 ans | |
| Mikael Dolsten | M | 65 | 15 ans | |
| Johanna Friedl-Naderer | F | 56 |
Biogen Idec Ltd.
Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 63 | 63,00% |
| Royaume-Uni | 38 | 38,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Trevor Anthony Mill
- Réseau Personnel
